Status:
UNKNOWN
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Lead Sponsor:
University of Mississippi Medical Center
Conditions:
Granulocyte Colony-Stimulating Factor
Chemotherapy-induced Neutropenia
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE4
Brief Summary
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection....
Eligibility Criteria
Inclusion
- Pediatric oncology patients will be eligible to participate in this study if they meet the following inclusion criteria:
- are between the ages of birth and 21 years old
- is diagnosed with an oncologic disease
- is being treated at UMMC Children's Cancer Clinic
- will receive G-CSF as part of their standard or experimental oncology treatment protocol between January 1, 2019 and December 31, 2019. Oncology treatment protocols are typically derived from the Children's Oncology Group standard of care or patients can be enrolled on a Children's Oncology Group treatment study.
- is within first four courses of chemotherapy treatment
Exclusion
- Patients will be excluded from the current study if:
- G-CSF was added to their oncology treatment protocol due to previous complications but for whom G-CSF was not part of their original treatment protocol.
- are being treated for relapsed disease
- has clinical evidence of bone marrow involvement
Key Trial Info
Start Date :
February 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03823950
Start Date
February 1 2019
End Date
June 1 2022
Last Update
March 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Univeristy of Mississippi Medical Center
Jackson, Mississippi, United States, 39216